As of November 6, 2026, Co-Diagnostics, Inc. is a publicly traded company (Nasdaq: CODX); its largest reported holder is Armistice Capital, with 9.99% on Schedule 13G of August 14, 2026. The largest insider holding is Ted Murphy, a director, with 224,167 shares (3.6% of shares outstanding), per Form 4 of May 27, 2025. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13G, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Co-Diagnostics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Co-Diagnostics, Inc. a real, registered company?
- Co-Diagnostics, Inc. files with the SEC under CIK 1692415 (its SEC filings).
- Its shares are listed under the ticker CODX on Nasdaq (SEC company record).
- Incorporated in Utah; business address in Salt Lake City, Utah, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under CO-DIAGNOSTICS, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Daniel Bohrer, Executive Vice President (Form 8-K filed 2026-09-04). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital (filed 2026-08-14).
Who are Co-Diagnostics, Inc.'s owners and officers?
Co-Diagnostics, Inc.: incorporated in Utah; business address in Salt Lake City, Utah; industry Surgical & Medical Instruments & Apparatus (Form D, 2026-09-04).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-14 | Armistice Capital, LLC | 9.99% |
| Schedule 13G/A, 2026-08-10 | Jane Street Group, LLC | 1.7% |
| Schedule 13G, 2026-06-03 | Jane Street Group, LLC | 6.4% |
| Schedule 13G/A, 2026-02-11 | Ayrton Capital LLC | 0% |
| Schedule 13G, 2025-11-13 | Ayrton Capital LLC | 9.7% |
| Schedule 13G/A, 2025-10-30 | The Vanguard Group | 3.54% |
| Schedule 13G/A, 2025-10-30 | Orca Capital Ag | 3.7% |
| Schedule 13G/A, 2025-10-30 | Orca Capital Ag | 9.9% |
| Schedule 13G/A, 2025-09-19 | Orca Capital Ag | 4.6% |
| Schedule 13G, 2025-09-18 | Orca Capital Ag | 9.9% |
Questions about who owns Co-Diagnostics, Inc.
Who owns Co-Diagnostics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Co-Diagnostics, Inc.: Armistice Capital, LLC (9.99%, Schedule 13G, filed 2026-08-14).
When did Armistice Capital, LLC buy into Co-Diagnostics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Armistice Capital, LLC on this page is the Schedule 13G, filed 2026-08-14, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Co-Diagnostics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Co-Diagnostics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Co-Diagnostics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-04 | Daniel Bohrer | Executive Vice President | appointed |
Which insiders own Co-Diagnostics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 224,167 shares (3.6% of shares outstanding) (Form 4, 2025-05-27).
- , the chief executive and a director: 27,893 shares (0.45% of shares outstanding) (Form 4, 2026-05-27).
- , the chief financial officer: 22,379 shares (0.36% of shares outstanding) (Form 4, 2026-05-27).
- , a director: 11,084 shares (0.18% of shares outstanding) (Form 4, 2026-05-27).
- , a director: 10,751 shares (0.17% of shares outstanding) (Form 4, 2026-05-27).
Shares outstanding: 6,252,319 as of 2026-08-11, from the company's latest SEC cover page.
How much has Co-Diagnostics, Inc. raised?
No fundraising or offering filing from Co-Diagnostics, Inc. is on file with us.
Keep reading
More on Co-Diagnostics, Inc. and the records around it.
Co-Diagnostics, Inc. elsewhere on the record
- Leadership changes Sep 2026
- 5%+ stake filings Aug 2026
Companies that share a holder
- Orca Capital AG also filed stake reports on 19 other companies: DarkIris Inc. (Oct 2026), Neo-Concept International Group Holdings Limited (Oct 2026), NFT Limited (Sep 2026)
- Ayrton Capital LLC also filed stake reports on 31 other companies: Bluejay Diagnostics, Inc. (Aug 2026), BTC Digital Ltd. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026)
- JANE STREET GROUP, LLC also filed stake reports on 73 other companies: AXT INC (Nov 2026), BIOVIE INC. (Nov 2026), Bitdeer Technologies Group (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/co-diagnostics